Home Newsfeeds Barclays Downgrades Robinhood Markets to Underweight

Barclays Downgrades Robinhood Markets to Underweight

Barclays analyst Ramsey El-Assal downgrades Robinhood Markets (NASDAQ:HOOD) from Equal-Weight to Underweight.

byBenzinga Newsdesk

August 31, 2022

1 minute read

Barclays analyst Ramsey El-Assal downgrades Robinhood Markets (NASDAQ:HOOD) from Equal-Weight to Underweight.

News

Study Finds That Masimo PVi Capable Of Predicting Fluid Responsiveness in Young Children Undergoing Neurosurgery

By Benzinga Newsdesk

March 9, 3:37 AM

Masimo (NASDAQ:MASI) today announced the findings of a prospective study published in Pediatrics International in which Dr. Ya-Fei Liu and colleagues at Peking University First Hospital in Beijing

MASI

Alzheimer’s Progression Slowed Down By Biogen’s New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

By Shanthi Rexaline

Today, 12:35 AM

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.

BIIB

News

BeautyHealth’s Hydrafacial Announces Partnership to Develop Breakthrough Exosome Booster

By Benzinga Newsdesk

September 14, 12:54 PM

Co-Created with Organicell, the first-to-market booster will address aging and inflammation through regenerative technology The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial, today announced a

SKIN

XRP Supporter’s Account Suspension Leads To Criticism Of Elon Musk, Raises Questions: What To Do If You Get The Same Treatment

By Mehab Qureshi

October 9, 7:38 AM

In a world where social media plays a significant role in communication, having your X, formerly Twitter, account suspended, locked, or limited can be a frustrating experience.

$XRP

Barclays Downgrades Robinhood Markets to Underweight

Related Posts

Study Finds That Masimo PVi Capable Of Predicting Fluid Responsiveness in Young Children Undergoing Neurosurgery

Alzheimer’s Progression Slowed Down By Biogen’s New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

BeautyHealth’s Hydrafacial Announces Partnership to Develop Breakthrough Exosome Booster

XRP Supporter’s Account Suspension Leads To Criticism Of Elon Musk, Raises Questions: What To Do If You Get The Same Treatment